Overall, single-cell analyses have revealed the complex interplay of cellular and molecular mechanisms driving adenomyosis, highlighting the potential for therapeutic interventions targeting Wnt signaling, angiogenic pathways, and pain-associated stem cell markers such as IGFBP5 and SFRP4. The gene discussed is IGFBP5; the disease is adenomyosis.